Medicare and Medicaid spending on GLP-1 drugs
How much do Medicare and Medicaid spend on GLP-1 drugs?
Medicare Part D spent $27.90 billion on GLP-1 drugs in 2024, CMS’s latest year, across 13 brand rows (2 of them insulin combination products), before manufacturer rebates; Ozempic alone was $12.97 billion. Medicaid pharmacy reimbursements for GLP-1 drugs were at least $12.05 billion in 2025 across at least 11,261,770 prescriptions, before the rebates manufacturers pay states.
These are aggregate program figures that CMS publishes: national totals by brand for Medicare Part D, and totals by state and quarter for Medicaid. No prescriber, pharmacy or patient is named. Figures are before rebates; see the CMS wording under each table.
Medicare Part D, by brand and year
Gross spending CMS reports for each GLP-1 brand in Part D, 2020 to 2024. “No data” means the CMS file has no figure for that brand in that year (for example, before the drug was sold).
| Ozempic | Semaglutide | $1,455,812,267 | $2,621,694,348 | $4,628,160,643 | $9,194,048,435 | $12,970,296,347 |
| Rybelsus | Semaglutide | $73,444,409 | $454,563,823 | $974,894,470 | $1,665,906,943 | $1,890,082,026 |
| Wegovy | Semaglutide | No data | No data | No data | $199,774 | $301,283,291 |
| Mounjaro | Tirzepatide | No data | No data | $144,035,152 | $2,361,384,157 | $6,336,942,641 |
| Zepbound | Tirzepatide | No data | No data | No data | No data | $387,343 |
| Victoza 3-Pak | Liraglutide | $1,545,815,415 | $1,422,292,583 | $1,238,594,872 | $1,004,635,145 | $203,063,050 |
| Victoza 2-Pak | Liraglutide | $349,476,159 | $334,897,957 | $319,205,509 | $317,213,565 | $77,832,721 |
| Liraglutide | Liraglutide | No data | No data | No data | No data | $48,095,824 |
| Trulicity | Dulaglutide | $3,284,873,062 | $4,702,174,724 | $6,225,291,668 | $7,363,856,224 | $5,454,134,725 |
| Bydureon Bcise | Exenatide Microspheres | $266,160,951 | $379,243,467 | $355,078,758 | $284,056,759 | $215,354,678 |
| Byetta | Exenatide | $47,676,632 | $37,988,662 | $27,500,961 | $20,645,626 | $15,877,480 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | $121,393,843 | $165,620,858 | $215,943,202 | $302,998,642 | $300,185,496 |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | $71,921,892 | $75,755,898 | $77,994,459 | $91,415,961 | $91,255,682 |
Totals by ingredient
| Ingredient | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Semaglutide (Ozempic, Rybelsus, Wegovy) | $1.53 billion | $3.08 billion | $5.60 billion | $10.86 billion | $15.16 billion |
| Tirzepatide (Mounjaro, Zepbound) | No data | No data | $144.0 million | $2.36 billion | $6.34 billion |
| Liraglutide (Victoza 3-Pak, Victoza 2-Pak, Liraglutide) | $1.90 billion | $1.76 billion | $1.56 billion | $1.32 billion | $329.0 million |
| Dulaglutide (Trulicity) | $3.28 billion | $4.70 billion | $6.23 billion | $7.36 billion | $5.45 billion |
| Exenatide (Bydureon Bcise, Byetta) | $313.8 million | $417.2 million | $382.6 million | $304.7 million | $231.2 million |
| Insulin glargine and lixisenatide (Soliqua 100-33) | $121.4 million | $165.6 million | $215.9 million | $303.0 million | $300.2 million |
| Insulin degludec and liraglutide (Xultophy 100-3.6) | $71.9 million | $75.8 million | $78.0 million | $91.4 million | $91.3 million |
| All GLP-1 rows | $7.22 billion | $10.19 billion | $14.21 billion | $22.61 billion | $27.90 billion |
Beneficiary counts are per brand and are not added up, because one person can fill prescriptions for more than one brand in a year.
Claims, beneficiaries and averages, 2024
| Ozempic | $12,970,296,347 | 10,417,182 | 1,952,637 | $1,245 | $6,642 |
| Rybelsus | $1,890,082,026 | 1,251,733 | 309,993 | $1,510 | $6,097 |
| Wegovy | $301,283,291 | 211,575 | 52,961 | $1,424 | $5,689 |
| Mounjaro | $6,336,942,641 | 5,105,397 | 894,581 | $1,241 | $7,084 |
| Zepbound | $387,343 | 353 | 245 | $1,097 | $1,581 |
| Victoza 3-Pak | $203,063,050 | 181,068 | 62,754 | $1,121 | $3,236 |
| Victoza 2-Pak | $77,832,721 | 108,521 | 41,126 | $717 | $1,893 |
| Liraglutide | $48,095,824 | 62,254 | 24,405 | $773 | $1,971 |
| Trulicity | $5,454,134,725 | 4,305,141 | 788,716 | $1,267 | $6,915 |
| Bydureon Bcise | $215,354,678 | 178,931 | 38,059 | $1,204 | $5,658 |
| Byetta | $15,877,480 | 11,712 | 3,043 | $1,356 | $5,218 |
| Soliqua 100-33 | $300,185,496 | 273,407 | 59,472 | $1,098 | $5,048 |
| Xultophy 100-3.6 | $91,255,682 | 57,197 | 13,672 | $1,595 | $6,675 |
CMS describes the Part D figures this way, in its catalog entry for the dataset:
“Drug spending metrics for Part D drugs are based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments.”
“The Part D spending metrics do not reflect any manufacturers’ rebates or other price concessions as CMS is prohibited from publicly disclosing such information.”
Medicare Part B
A search of CMS’s Medicare Part B Spending by Drug file (2020 to 2024, read Nov 15, 2026) for generic names containing “glutide”, “xenatide”, “tirzepatide”, “lixisenatide” returned no rows. CMS describes that file as covering “drugs administered in doctors’ offices and other outpatient settings,” and its Part D file as covering “drugs patients generally administer themselves.” This is a statement about that file only.
“Drug spending metrics for Part B drugs represent the full value of the product, including the Medicare payment and beneficiary liability.”
Medicaid, national
Pharmacies were reimbursed at least $12.05 billion for GLP-1 drugs paid through Medicaid nationwide in 2025, across at least 11,261,770 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 81 rows of 513, so these figures are floors.
| 2020 | at least $283,898,491 | No data | $567,508,684 | at least $596,408,518 | at least $193,861,115 | at least $671,511 | $7,761,540 | $5,421,897 | at least $1,655,531,756 |
| 2021 | at least $554,820,690 | No data | $680,639,494 | at least $1,188,068,204 | at least $134,241,933 | at least $1,080,158 | $9,594,531 | $4,796,567 | at least $2,573,241,576 |
| 2022 | at least $1,149,248,802 | at least $34,060,250 | $722,777,322 | $2,153,391,817 | at least $98,166,895 | at least $359,908 | $12,192,603 | $4,138,825 | at least $4,174,336,421 |
| 2023 | at least $2,911,348,586 | at least $439,944,750 | $722,050,605 | $2,839,397,030 | at least $82,702,773 | at least $11,027 | $9,422,199 | $3,295,077 | at least $7,008,172,046 |
| 2024 | at least $5,107,538,873 | at least $1,205,743,835 | $294,458,438 | $2,163,300,920 | at least $66,016,586 | No data | $6,859,607 | $2,280,203 | at least $8,846,198,462 |
| 2025 | at least $6,613,338,249 | at least $3,323,545,465 | $145,922,324 | $1,948,292,919 | at least $15,363,655 | No data | $4,455,588 | $1,460,353 | at least $12,052,378,553 |
| 2026 (Q1) | at least $1,251,443,577 | at least $911,460,172 | at least $24,183,285 | $391,170,412 | at least $137,347 | No data | $762,625 | $275,378 | at least $2,579,432,797 |
National figures are the rows CMS publishes under the state code XX. The latest year shows only the quarters CMS has posted.
By product, 2025
| Bydureon | at least $12,367,705 | at least 15,101 | 3 of 9 |
| Byetta | at least $2,689,012 | at least 3,211 | 4 of 16 |
| Liraglutide (generic name listing) | $79,063,400 | 182,428 | 0 of 52 |
| Mounjaro | at least $1,515,725,769 | at least 1,416,807 | 21 of 96 |
| Ozempic | at least $3,754,483,078 | at least 3,695,710 | 6 of 53 |
| Rybelsus | at least $258,033,553 | at least 201,299 | 11 of 35 |
| Saxenda | $34,485,966 | 29,057 | 0 of 8 |
| Soliqua | $4,455,588 | 5,168 | 0 of 8 |
| Trulicity | $1,948,292,919 | 1,940,795 | 0 of 64 |
| Victoza | $32,372,958 | 51,226 | 0 of 16 |
| Wegovy | at least $2,600,821,618 | at least 1,995,718 | 4 of 44 |
| Xultophy | $1,460,353 | 1,142 | 0 of 8 |
| Zepbound | at least $1,807,819,696 | at least 1,723,702 | 32 of 98 |
| Exenatide (generic name listing) | $306,938 | 406 | 0 of 6 |
Medicaid, by state
Each state’s GLP-1 rows for 2025, all quarters. Each state name links to that state’s page, with every year from 2020 and each quarter.
| Alabama | at least $72,334,685 | at least 71,831 | 57 of 171 |
| Alaska | at least $22,152,586 | at least 23,249 | 102 of 202 |
| Arizona | at least $98,252,621 | at least 93,645 | 76 of 215 |
| Arkansas | at least $18,871,001 | at least 24,039 | 111 of 279 |
| California | at least $3,462,543,976 | at least 3,090,452 | 50 of 319 |
| Colorado | at least $127,199,098 | at least 123,012 | 69 of 284 |
| Connecticut | at least $202,814,053 | at least 174,553 | 21 of 141 |
| Delaware | at least $21,354,918 | at least 55,674 | 104 of 218 |
| District of Columbia | at least $28,122,591 | at least 27,754 | 115 of 265 |
| Florida | at least $128,079,710 | at least 133,482 | 85 of 252 |
| Georgia | at least $52,526,193 | at least 59,456 | 76 of 283 |
| Hawaii | at least $33,872,236 | at least 30,478 | 49 of 144 |
| Idaho | at least $46,072,822 | at least 45,954 | 42 of 156 |
| Illinois | at least $305,552,662 | at least 288,522 | 65 of 287 |
| Indiana | at least $204,764,005 | at least 190,162 | 82 of 297 |
| Iowa | at least $87,363,112 | at least 88,518 | 83 of 227 |
| Kansas | at least $53,573,102 | at least 50,903 | 36 of 161 |
| Kentucky | at least $238,314,570 | at least 274,538 | 97 of 292 |
| Louisiana | at least $230,946,267 | at least 230,359 | 63 of 229 |
| Maine | at least $40,616,132 | at least 41,655 | 41 of 162 |
| Maryland | at least $142,812,988 | at least 148,648 | 119 of 308 |
| Massachusetts | at least $404,519,821 | at least 399,030 | 98 of 345 |
| Michigan | at least $681,063,451 | at least 608,028 | 102 of 366 |
| Minnesota | at least $255,696,545 | at least 230,594 | 79 of 337 |
| Mississippi | at least $70,718,721 | at least 61,646 | 115 of 285 |
| Missouri | at least $284,863,196 | at least 285,105 | 47 of 165 |
| Montana | at least $22,195,107 | at least 22,719 | 47 of 139 |
| Nebraska | at least $36,117,422 | at least 37,335 | 48 of 144 |
| Nevada | at least $81,868,395 | at least 70,939 | 84 of 279 |
| New Hampshire | at least $37,487,064 | at least 34,652 | 67 of 190 |
| New Jersey | at least $151,445,199 | at least 165,667 | 135 of 289 |
| New Mexico | at least $64,499,377 | at least 64,832 | 113 of 255 |
| New York | at least $941,187,086 | at least 816,616 | 67 of 245 |
| North Carolina | at least $589,996,654 | at least 484,712 | 94 of 338 |
| North Dakota | at least $3,605,150 | at least 5,852 | 57 of 100 |
| Ohio | at least $406,954,834 | at least 425,347 | 115 of 357 |
| Oklahoma | at least $83,573,455 | at least 82,365 | 66 of 264 |
| Oregon | at least $67,351,293 | at least 72,793 | 106 of 290 |
| Pennsylvania | at least $951,405,819 | at least 844,001 | 107 of 366 |
| Puerto Rico | at least $51,822,634 | at least 48,732 | 37 of 148 |
| Rhode Island | at least $48,888,755 | at least 46,691 | 81 of 250 |
| South Carolina | at least $64,945,523 | at least 65,093 | 105 of 279 |
| South Dakota | at least $15,709,847 | at least 15,602 | 40 of 113 |
| Tennessee | at least $144,104,065 | at least 136,023 | 45 of 189 |
| Texas | at least $179,016,062 | at least 172,353 | 114 of 244 |
| Utah | at least $28,648,950 | at least 28,007 | 97 of 247 |
| Vermont | at least $18,537,316 | at least 17,163 | 38 of 133 |
| Virginia | at least $230,109,559 | at least 227,621 | 123 of 329 |
| Washington | at least $82,653,211 | at least 111,202 | 98 of 281 |
| West Virginia | at least $91,584,548 | at least 94,999 | 53 of 149 |
| Wisconsin | at least $327,847,844 | at least 302,672 | 18 of 168 |
| Wyoming | at least $2,244,963 | at least 2,315 | 76 of 140 |
A state marked “at least” or “Suppressed” has rows CMS withheld, so its full amount is unknown and it cannot be ranked against other states; its place in this order reflects only the rows CMS published.
2026, quarters posted so far (Q1)
| Alabama | at least $22,601,198 | at least 21,926 | 14 of 47 |
| Alaska | at least $5,305,125 | at least 5,385 | 14 of 39 |
| Arizona | at least $17,261,573 | at least 15,751 | 18 of 55 |
| Arkansas | at least $7,485,924 | at least 8,394 | 28 of 74 |
| California | at least $537,681,425 | at least 498,619 | 16 of 86 |
| Colorado | at least $40,344,875 | at least 38,302 | 25 of 81 |
| Connecticut | at least $45,117,089 | at least 35,591 | 9 of 40 |
| Delaware | at least $5,035,559 | at least 10,855 | 31 of 58 |
| District of Columbia | at least $7,163,586 | at least 7,410 | 41 of 83 |
| Florida | at least $29,953,764 | at least 29,769 | 21 of 65 |
| Georgia | at least $14,835,416 | at least 16,345 | 25 of 83 |
| Hawaii | at least $7,389,266 | at least 6,109 | 9 of 35 |
| Idaho | at least $12,391,377 | at least 12,339 | 11 of 40 |
| Illinois | at least $55,278,302 | at least 52,093 | 11 of 71 |
| Indiana | at least $46,413,529 | at least 41,444 | 19 of 82 |
| Iowa | at least $20,245,786 | at least 19,750 | 32 of 67 |
| Kansas | at least $9,495,187 | at least 8,638 | 15 of 42 |
| Kentucky | at least $48,092,559 | at least 57,534 | 30 of 79 |
| Louisiana | at least $44,615,662 | at least 42,742 | 27 of 71 |
| Maine | at least $11,179,202 | at least 11,118 | 11 of 40 |
| Maryland | at least $39,661,203 | at least 39,617 | 39 of 94 |
| Massachusetts | at least $121,171,872 | at least 116,367 | 23 of 83 |
| Michigan | at least $155,810,081 | at least 139,557 | 33 of 99 |
| Minnesota | at least $56,052,562 | at least 50,352 | 18 of 85 |
| Mississippi | at least $20,785,939 | at least 17,804 | 28 of 76 |
| Missouri | at least $121,205,304 | at least 116,884 | 10 of 38 |
| Montana | at least $5,733,788 | at least 5,674 | 11 of 33 |
| Nebraska | at least $9,426,206 | at least 9,278 | 14 of 41 |
| Nevada | at least $24,907,445 | at least 19,396 | 27 of 88 |
| New Hampshire | at least $3,857,847 | at least 3,913 | 18 of 45 |
| New Jersey | at least $27,399,401 | at least 28,333 | 36 of 74 |
| New Mexico | at least $16,567,965 | at least 16,659 | 31 of 73 |
| New York | at least $255,741,996 | at least 217,802 | 16 of 58 |
| North Carolina | at least $145,713,648 | at least 119,143 | 30 of 99 |
| North Dakota | at least $2,191,959 | at least 2,335 | 15 of 26 |
| Ohio | at least $88,482,152 | at least 90,654 | 26 of 96 |
| Oklahoma | at least $19,672,034 | at least 19,435 | 25 of 75 |
| Oregon | at least $16,562,209 | at least 17,838 | 32 of 81 |
| Pennsylvania | at least $69,383,793 | at least 68,534 | 27 of 85 |
| Puerto Rico | at least $11,234,524 | at least 10,786 | 8 of 25 |
| Rhode Island | at least $13,328,198 | at least 12,340 | 23 of 69 |
| South Carolina | at least $15,775,344 | at least 16,018 | 31 of 71 |
| South Dakota | at least $4,116,128 | at least 3,936 | 17 of 34 |
| Tennessee | at least $70,662,190 | at least 62,734 | 14 of 54 |
| Texas | at least $54,896,332 | at least 50,835 | 30 of 72 |
| Utah | at least $7,788,657 | at least 7,689 | 34 of 79 |
| Vermont | at least $5,807,912 | at least 5,237 | 6 of 33 |
| Virginia | at least $52,912,733 | at least 51,409 | 33 of 87 |
| Washington | at least $24,933,072 | at least 30,841 | 22 of 72 |
| West Virginia | at least $25,021,572 | at least 25,520 | 10 of 41 |
| Wisconsin | at least $99,701,709 | at least 91,305 | 4 of 45 |
| Wyoming | at least $1,621,808 | at least 1,556 | 9 of 38 |
A state marked “at least” or “Suppressed” has rows CMS withheld, so its full amount is unknown and it cannot be ranked against other states; its place in this order reflects only the rows CMS published.
The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:
“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”
Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”
CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.
Questions answered from this data
- How much did Medicare Part D spend on Ozempic in 2024?
- How much has Medicare Part D spending on GLP-1 drugs grown since 2020?
- How much does Medicaid spend on GLP-1 drugs in each state?
How the rows are chosen
Part D rows are kept when CMS’s generic name is exactly one of: Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, Exenatide, Lixisenatide, Insulin glargine and lixisenatide, Insulin degludec and liraglutide (with “Exenatide Microspheres” counted as exenatide), using CMS’s “Overall” row for each brand. Medicaid rows are kept when the first word of the product name CMS gives (the first 10 characters of the FDA listing name) is one of the brand or generic names listed on the methodology page. Retatrutide and cagrilintide were also searched for in both files; neither name appears in either.
Common questions
Do these figures include manufacturer rebates?
No. CMS says the Part D figures do not reflect manufacturer rebates or other price concessions, and its Medicaid total amount reimbursed is not reduced by the rebates manufacturers pay states.
Why do some Medicaid figures say “at least” or “Suppressed”?
CMS suppresses some state rows and leaves their counts and amounts blank. A total that includes suppressed rows is shown as at least the published sum; a total where every row is suppressed is shown as suppressed, never as zero.
Does Medicare Part D cover Wegovy and Zepbound?
This page reports only what CMS’s spending files show. Wegovy and Zepbound appear in the Part D file with the spending and beneficiary counts shown in the table above; the file does not say what each claim was for.
Sources
- CMS Medicare Part D Spending by Drug (data.cms.gov)
- CMS Medicare Part B Spending by Drug (data.cms.gov)
- CMS Medicaid State Drug Utilization Data (Medicaid.gov)
- State Drug Utilization Data 2020 (data.medicaid.gov)
- State Drug Utilization Data 2021 (data.medicaid.gov)
- State Drug Utilization Data 2022 (data.medicaid.gov)
- State Drug Utilization Data 2023 (data.medicaid.gov)
- State Drug Utilization Data 2024 (data.medicaid.gov)
- State Drug Utilization Data 2025 (data.medicaid.gov)
- State Drug Utilization Data 2026 (data.medicaid.gov)
Records last pulled Nov 15, 2026. Every entry links to the original public record.